Israeli researchers at a blood cancer conference in the US reported a lymphoma treatment that can achieve 100% survival rates ...
A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...
In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.
B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of ...
News-Medical.Net on MSN
New trial shows major survival gains with epcoritamab added to standard R2 therapy
In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction ...
R 2 is the only second-line alternative to chemoimmunotherapy-based treatment for patients with relapsed/refractory ...
Zanubrutinib combined with R-CHOP showed high efficacy in DLBCL patients with activated BCR signaling and specific genetic mutations, achieving a 91.4% ORR and 79.3% CR rate. The study's primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback